```html

Xanthomas Planus: A Complete Patient‑Friendly Guide

Overview

Xanthomas planus, also spelled “planar xanthoma,” are flat or slightly raised yellow‑orange plaques that appear on the skin. They are a type of cutaneous xanthoma, which means they result from an accumulation of lipid‑laden macrophages (foam cells) in the dermis. While the lesions themselves are benign, they often signal underlying lipid metabolism disorders such as familial hypercholesterolemia, hypertriglyceridemia, or rare storage diseases.

Who it affects: Xanthomas planus can occur at any age, but most cases are reported in:

• Children and adolescents with inherited lipid disorders (≈ 30–40% of pediatric cases).
• Adults aged 30‑60 years with uncontrolled hyperlipidemia or metabolic syndrome.
• Individuals with certain systemic diseases (e.g., primary biliary cholangitis, monoclonal gammopathies).

Prevalence: Exact population data are limited because planar xanthomas are often under‑reported. In a 2019 review of 2,642 patients with familial hypercholesterolemia, 5.8% had planar xanthomas, making them one of the less common but clinically significant cutaneous markers of dyslipidemia [1].

Symptoms

Planar xanthomas are primarily a skin manifestation, but they can be associated with systemic signs of lipid disturbances.

Typical dermatologic findings

• Color: Yellow‑orange to golden hue, often becoming more pronounced after light exposure.
• Shape & size: Flat, well‑demarcated plaques that range from a few millimeters to several centimeters in diameter.
• Location: Common on the neck, elbows, knees, palms, abdomen, and periorbital area (especially the eyelids – “xanthelasma”).
• Texture: Smooth or slightly verrucous; lesions are typically non‑painful and non‑pruritic.
• Number: Can be solitary or multiple; in severe lipid disorders, lesions may coalesce into larger plaques.

Systemic clues that may accompany xanthomas planus

• Persistent high cholesterol or triglyceride levels.
• Family history of early‑onset heart disease.
• Abdominal pain or hepatomegaly (suggesting fatty liver disease).
• Fatigue, shortness of breath, or claudication due to atherosclerotic vascular disease.

Causes and Risk Factors

Planar xanthomas develop when excess lipids are deposited in the skin. The key pathways include:

Primary (genetic) causes

• Familial hypercholesterolemia (FH) – LDL‑receptor mutations lead to markedly elevated LDL‑C levels.
• Familial combined hyperlipidemia – Overproduction of VLDL and LDL particles.
• Rare storage diseases – e.g., Niemann‑Pick disease, Gaucher disease, where macrophages cannot properly catabolize lipids.

Secondary (acquired) causes

• Uncontrolled type 2 diabetes mellitus.
• Obesity and metabolic syndrome.
• Chronic liver disease (primary biliary cholangitis, cholestasis).
• Medications that raise lipids (e.g., cyclosporine, some antiretrovirals).

Risk factors

• First‑degree relative with hyperlipidemia or early heart attack.
• Smoking – accelerates atherosclerosis and may worsen lipid profiles.
• Sedentary lifestyle and dietary patterns high in saturated/trans fats.
• Age (risk rises after the third decade) and male sex (though women often present with xanthelasma).

Diagnosis

Diagnosis combines a careful skin examination with laboratory and imaging studies to uncover the underlying lipid disorder.

Clinical assessment

• Visual inspection of lesions – dermatologists often recognize the characteristic yellow‑orange hue.
• Dermatoscopy – may reveal clustered yellowish structures corresponding to foam cells.
• Skin biopsy (rarely needed) – Histology shows lipid‑laden macrophages in the papillary dermis, confirming a xanthoma.

Laboratory tests

• Lipid panel – fasting total cholesterol, LDL‑C, HDL‑C, triglycerides.
• Genetic testing for FH (LDLR, APOB, PCSK9 mutations) when familial hypercholesterolemia is suspected.
• Liver function tests if cholestatic disease is a concern.
• Blood glucose and HbA1c to evaluate for diabetes.

Imaging & additional studies

• Carotid ultrasound or coronary calcium scoring to assess atherosclerotic burden.
• Abdominal ultrasound or MRI if fatty liver disease is suspected.

Because planar xanthomas can be the first visible sign of a serious lipid disorder, prompt evaluation is essential.

Treatment Options

Treatment focuses on two goals: removing or reducing the skin lesions and, more importantly, correcting the underlying lipid abnormality.

1. Lipid‑lowering medications

• Statins (e.g., atorvastatin, rosuvastatin) – first‑line for LDL‑C reduction; can lower lesion size in 6‑12 months.
• Ezetimibe – added when statin alone is insufficient.
• PCSK9 inhibitors (evolocumab, alirocumab) – especially for homozygous FH or statin‑intolerant patients.
• Fibrates (gemfibrozil, fenofibrate) – useful when triglycerides dominate.
• Niacin – modest effect on LDL‑C; limited by flushing side‑effects.

2. Non‑pharmacologic measures

• Dietary changes – a Mediterranean‑style diet rich in fiber, nuts, fish, and olive oil; limit saturated fats, trans fats, and refined sugars.
• Physical activity – at least 150 min of moderate‑intensity aerobic exercise per week.
• Weight management – 5‑10 % weight loss can improve LDL‑C and triglycerides.
• Smoking cessation – improves overall lipid profile and cardiovascular risk.

3. Dermatologic procedures (for persistent lesions)

• Laser therapy – CO₂ or Nd:YAG lasers can vaporize plaques; multiple sessions often required.
• Excimer laser or intense pulsed light (IPL) – useful for thinner lesions.
• Surgical excision – considered for isolated, large plaques.
• Cryotherapy – limited data; may cause hypopigmentation.

4. Emerging therapies

• Antisense oligonucleotides (e.g., volanesorsen) for severe hypertriglyceridemia.
• Gene‑editing approaches (CRISPR‑Cas9) – still experimental but hold promise for lifetime correction of FH.

Living with Xanthomas Planus

Even after lesions resolve, ongoing management is essential because the skin findings reflect systemic lipid imbalance.

Daily management tips

• Medication adherence – take statins or other agents exactly as prescribed; use a pill‑box or smartphone reminder.
• Regular lipid monitoring – at least every 3‑6 months in the first year, then annually if stable.
• Skin care – gentle cleansers, moisturizers without occlusive oils; avoid excessive sun exposure which can darken plaques.
• Nutrition log – track meals for 1–2 weeks to identify hidden sources of saturated fat.
• Physical activity log – aim for consistency; short bouts spread through the day are acceptable.
• Family screening – encourage first‑degree relatives to have lipid panels; early detection can prevent future xanthomas and cardiovascular events.

Psychosocial support

Visible skin lesions can affect self‑esteem. Consider:

• Joining patient support groups (e.g., FH Foundation).
• Speaking with a mental‑health professional if anxiety or depression arises.
• Discussing cosmetic options with a dermatologist once lipid levels are controlled.

Prevention

Because planar xanthomas are a manifestation of dyslipidemia, primary prevention targets the lipid disorder itself.

• Screen early – Universal lipid screening for children ≥9 years and again at 11‑12 years (American Academy of Pediatrics recommendation).
• Adopt heart‑healthy eating patterns – Emphasize fruits, vegetables, whole grains, and omega‑3 rich fish.
• Maintain a healthy weight – Body mass index (BMI) < 25 kg/m² for most adults.
• Control diabetes – Target HbA1c < 7 % (individualized).
• Regular exercise – Combine aerobic and resistance training.
• Avoid tobacco and limit alcohol – Both worsen lipid profiles.
• Medication prophylaxis – In high‑risk families (e.g., heterozygous FH), consider early statin therapy per pediatric guidelines.

Complications

If the underlying lipid disturbance remains untreated, the following complications may arise:

• Atherosclerotic cardiovascular disease (ASCVD) – myocardial infarction, stroke, peripheral artery disease.
• Pancreatitis – especially with severe hypertriglyceridemia (> 1000 mg/dL).
• Liver disease – non‑alcoholic fatty liver disease progressing to steatohepatitis or cirrhosis.
• Secondary xanthomas – Tendon (e.g., Achilles) and eruptive xanthomas may develop, indicating worsening lipid control.
• Psychological impact – Persistent disfiguring lesions can lead to social withdrawal.

When to Seek Emergency Care

---

Sources: [1] Nordestgaard BG et al. “Familial hypercholesterolaemia is underdiagnosed and undertreated in general practice.” European Heart Journal. 2019;40:2293‑2300.
[2] Mayo Clinic. “Xanthomas: Causes, symptoms, and treatment.” 2024.
[3] National Heart, Lung, and Blood Institute. “High Blood Cholesterol.” Updated 2023.
[4] American Academy of Pediatrics. “Lipids Screening Guidelines.” 2022.
[5] Cleveland Clinic. “Statins: Benefits, risks, and side effects.” 2024.

```